Literature DB >> 7634047

Multiple drug resistance in osteosarcoma.

R N Rosier1, L A Teot, D G Hicks, C Schwartz, R J O'Keefe, J E Puzas.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 7634047      PMCID： PMC2329065     

Source DB:  PubMed          Journal:  Iowa Orthop J        ISSN： 1541-5457


× No keyword cloud information.
  14 in total

Review 1.  Experience with multiagent chemotherapy for osteosarcoma. Improved outcome.

Authors:  A M Goorin; J W Andersen
Journal:  Clin Orthop Relat Res       Date:  1991-09       Impact factor: 4.176

2.  Osteosarcoma: pathology and classification.

Authors:  K K Unni; D C Dahlin
Journal:  Semin Roentgenol       Date:  1989-07       Impact factor: 0.800

3.  Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures.

Authors:  S M Hsu; L Raine; H Fanger
Journal:  J Histochem Cytochem       Date:  1981-04       Impact factor: 2.479

4.  Expression of a multidrug resistance gene in human cancers.

Authors:  L J Goldstein; H Galski; A Fojo; M Willingham; S L Lai; A Gazdar; R Pirker; A Green; W Crist; G M Brodeur
Journal:  J Natl Cancer Inst       Date:  1989-01-18       Impact factor: 13.506

5.  Expression of the multidrug resistance gene in osteosarcoma: a pilot study.

Authors:  J S Wunder; R S Bell; L Wold; I L Andrulis
Journal:  J Orthop Res       Date:  1993-05       Impact factor: 3.494

Review 6.  Radiation and pagetic osteogenic sarcomas.

Authors:  J H Healey; D Buss
Journal:  Clin Orthop Relat Res       Date:  1991-09       Impact factor: 4.176

7.  P-glycoprotein in human sarcoma: evidence for multidrug resistance.

Authors:  J H Gerlach; D R Bell; C Karakousis; H K Slocum; N Kartner; Y M Rustum; V Ling; R M Baker
Journal:  J Clin Oncol       Date:  1987-09       Impact factor: 44.544

8.  Chemotherapy for nonmetastatic osteogenic sarcoma: the Memorial Sloan-Kettering experience.

Authors:  P A Meyers; G Heller; J Healey; A Huvos; J Lane; R Marcove; A Applewhite; V Vlamis; G Rosen
Journal:  J Clin Oncol       Date:  1992-01       Impact factor: 44.544

9.  Prognostic factors in osteosarcoma. A review of 20 year's experience at the University of Pittsburgh Health Center Hospitals.

Authors:  P E Scranton; F A DeCicco; R S Totten; E J Yunis
Journal:  Cancer       Date:  1975-12       Impact factor: 6.860

Review 10.  P-glycoproteins in pathology: the multidrug resistance gene family in humans.

Authors:  R S Weinstein; J R Kuszak; L F Kluskens; J S Coon
Journal:  Hum Pathol       Date:  1990-01       Impact factor: 3.466
View more
  4 in total

Review 1.  In situ hybridization in the pathology laboratory: general principles, automation, and emerging research applications for tissue-based studies of gene expression.

Authors:  David G Hicks; Gabe Longoria; James Pettay; Tom Grogan; Shannon Tarr; Raymond Tubbs
Journal:  J Mol Histol       Date:  2004-08       Impact factor: 2.611

2.  Conserved molecular mechanisms underlying the effects of small molecule xenobiotic chemotherapeutics on cells.

Authors:  Hemant Sarin
Journal:  Mol Clin Oncol       Date:  2015-12-16

3.  High expression of MACC1 predicts poor prognosis in patients with osteosarcoma.

Authors:  Kai Zhang; Yonggang Zhang; Huimin Zhu; Na Xue; Jie Liu; Chao Shan; Qing Zhu
Journal:  Tumour Biol       Date:  2013-09-25

4.  Anlotinib Reverses Multidrug Resistance (MDR) in Osteosarcoma by Inhibiting P-Glycoprotein (PGP1) Function In Vitro and In Vivo.

Authors:  Gangyang Wang; Lingling Cao; Yafei Jiang; Tao Zhang; Hongsheng Wang; Zhuoying Wang; Jing Xu; Min Mao; Yingqi Hua; Zhengdong Cai; Xiaojun Ma; Shuo Hu; Chenghao Zhou
Journal:  Front Pharmacol       Date:  2022-01-17       Impact factor: 5.810
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.